Hormonal
Highly effective anti-obesity medications (AOMs), specifically nutrient-stimulated hormone-based therapies (NuSH-BTs) like semaglutide and tirzepatide, induce mean weight loss of 15% or more, significantly outperforming lifestyle interventions alone.
If you have obesity, lifestyle changes alone often result in modest, temporary weight loss. Newer hormone-based medications (like semaglutide or tirzepatide) are highly effective, causing an average 15-20% weight loss. These require a prescription and slow dose titration to manage side effects, but they offer a significant advantage over lifestyle changes alone for achieving substantial health improvements.
Highly-effective AOMs, including nutrient-stimulated hormone-based therapies, induce mean weight loss of 15% or more.
Why this rating
Based on multiple RCTs and large-scale trials cited in the review.
Source
Approach to Obesity Treatment in Primary Care
Susan Z. Yanovski et al. · JAMA Internal Medicine · 2024
DOI 10.1001/jamainternmed.2023.8526
More from this paper
- Discontinuation of anti-obesity medications (AOMs) after weight loss leads to significant weight regain (approx. two-thirds of lost weight) and reversal of cardiometabolic improvements, necessitating long-term treatment.Strong
- Lifestyle interventions (diet and physical activity) alone result in modest weight loss (2-9%) and are often insufficient for significant health improvements, though they remain a fundamental component of obesity management.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →